Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme system in the gastric parietal cell.
## Primary Indications
* Short-term treatment (up to 8 weeks) of erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
* Prophylaxis of stress-related mucosal bleeding (off-label/institutional protocol dependent).
## Adult Dosing
* **Erosive Esophagitis (Treatment):** 40 mg PO or IV once daily for up to 8 weeks.
* **Erosive Esophagitis (Maintenance):** 40 mg PO once daily.
* **Hypersecretory Conditions:** Starting dose 40 mg PO twice daily. Doses up to 240 mg/day have been used; adjust based on clinical need and gastric acid output.
* **IV Bolus:** 40 mg IV once daily (duration: 7–10 days, transition to oral as soon as feasible).
## Pediatric Dosing
* **GERD/Erosive Esophagitis (Age 5 years and older):**
* 15 kg to <40 kg: 20 mg once daily.
* 40 kg and greater: 40 mg once daily.
* **Safety/Efficacy:** Safety in pediatric patients <5 years is not established.
## Dose Adjustments
* **Hepatic Impairment:** Reduce frequency or maximum daily dose in severe impairment; monitor hepatic enzymes.
* **Renal Impairment:** No dosage adjustment necessary.
* **Geriatric:** No dosage adjustment necessary, though use the lowest effective dose for the shortest duration.
## Contraindications
* Hypersensitivity to pantoprazole or substituted benzimidazoles.
* Concomitant use with rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypomagnesemia, vitamin B12 deficiency (long-term use), acute interstitial nephritis, cutaneous/systemic lupus erythematosus.
## Key Drug Interactions
* **pH-Dependent Drugs:** Atazanavir, nelfinavir, and iron salts (reduced absorption). Avoid concomitant use with rilpivirine.
* **Methotrexate:** Potential increase in serum levels/toxicity, particularly in high-dose therapy.
* **Clopidogrel:** Potential reduced antiplatelet effect, although clinical significance is debated.
## Monitoring
* Monitor for signs of hypomagnesemia (e.g., muscle spasms, tremors, arrhythmias) during prolonged therapy.
* Monitor B12 levels if therapy exceeds one year.
* Evaluate need for continued therapy periodically to avoid unnecessary long-term use.
## Clinical Pearls
* **Administration:** Oral tablets should be swallowed whole; do not crush or chew. IV administration must be performed via dedicated line or Y-site using a 0.22-micron filter.
* **Timing:** Administer oral doses 30–60 minutes before a meal for optimal acid suppression.
* **Risk:** Long-term PPI use is associated with an increased risk of bone fractures (osteoporosis-related) and should be used with caution in high-risk patients.
* **Dose Limits:** Institutional protocols for stress ulcer prophylaxis often favor lower doses or bolus/infusion schedules; verify local guidelines.
***
**Disclaimer:** This information is for educational purposes only. Always consult the most current product labeling, institutional pharmacy protocols, and clinical guidelines before prescribing or administering any medication.
